Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;64(4).
doi: 10.1002/pbc.26308. Epub 2016 Oct 27.

Salvage Therapy for Refractory Hemophagocytic Lymphohistiocytosis: A Review of the Published Experience

Affiliations
Review

Salvage Therapy for Refractory Hemophagocytic Lymphohistiocytosis: A Review of the Published Experience

Rebecca A Marsh et al. Pediatr Blood Cancer. .

Abstract

Hemophagocytic lymphohistioytosis (HLH) is a severe, life-threatening hyperinflammatory disorder that requires prompt diagnosis and treatment. Approximately, 25-50% of patients with HLH fail to achieve remission with established regimens that include dexamethasone and etoposide, or methylprednisolone and antithymocyte globulin (ATG). Some of these patients may require salvage or alternative therapeutic approaches. There is a paucity of literature regarding effective salvage therapies for patients with refractory HLH. In this review, we summarize the published experience of four therapeutics reported for using at least two patients with HLH refractory to dexamethasone and etoposide or methylprednisolone and ATG.

Keywords: HLH; hemophagocytic lymphohistiocytosis; refractory HLH; salvage therapy.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback